2022

• CyhoeddwydEconomic evaluation of Tislelizumab Versus Chemotherapy as Second Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
  Shi, F., He, Z., Su, H., Wang, L. & Han, S., 16 Tach 2022, Yn: Frontiers in Pharmacology. 13
  Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid